Laboratory-based Prediction of Drug Biopharmaceutical Properties
Noha Mohamed Zaki Rayad*
Noha Mohamed Zaki Rayad, PhD, lecturer of Pharmaceutics, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt
- *Corresponding Author:
- Dr. Noha Mohamed Zaki Rayad, PhD
lecturer of Pharmaceutics
Faculty of Pharmacy
Ain Shams University, Abbassia, Cairo, Egypt
Tel: (+202) 24102107
Fax: (+202) 24032059
E-mail: [email protected]
Received Date: November 28, 2011; Accepted Date: December 05, 2011; Published Date: December 07, 2011
Citation: Zaki Rayad NM (2011) Laboratory-based Prediction of Drug Biopharmaceutical Properties. J Bioequiv Availab 3: x-xi. doi: 10.4172/jbb.10000e10
Copyright: © 2011 Zaki Rayad NM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Bioavailability (BA), i.e. the amount of drug that is absorbed from the gut and delivered intact to the systemic circulation, is a main concern in the drug development process. Pharmaceutical scientists are striving to achieve as high BA as possible (one that approaches that after intravenous bolus). Biopharmaceutics is concerned with the physicochemical properties of a drug, the formulation in which the drug is placed as well as the physiology of the human being that would eventually lead to a high BA. The key biopharmaceutical properties are: solubility of drug in the gastrointestinal (GI) fluids and its permeability through the intestinal mucosa. The goal of connecting in vitro and in vivo behaviour of a drug product is an endless goal for research, industry and regulatory societies. It is important to highlight how far the science has progressed in this regard but also how far it has to go to achieve this goal. Early in the drug discovery process, the favourable biopharmaceutical drug properties were acknowledged especially after these properties were represented by the renowned Biopharmaceutical Classification System (BCS). The guidelines for the BCS were introduced by the Food and Drug Administration (FDA) to simplify the production of generic drugs (FDA 2000). The drug discovery process was inspired by the BCS to adopt the structure-property relationship (SQR) rather than the traditional paradigm of structure-activity relationship (SAR). In this context, the lead structures in the drug discovery process were not only optimized with regard to their pharmacological properties but equally important, their biopharmaceutical properties.